A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.
Advanced KRAS G12D Mutant Solid Tumors
DRUG: HRS-4642|DRUG: Adebrelimab|DRUG: SHR-9839|DRUG: Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection|DRUG: Cetuximab Solution for Infusion
Phase IB: Safety endpoints: adverse events (AEs)., Assess safety and tolerability by way of adverse events (CTCAE v5.0)., 24 months|Phase IB： Maximum tolerated dose (MTD), Incidence and category of dose limiting toxicities (DLTs) during the first 21-day cycle of treatment., From Day 1 to Day 21|Phase IB：Recommended phase 2 dose (RP2D), RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in dose escalation and dose expansion stages., 24 months|Phase II: Overall response rate (ORR)., Evaluated by RECIST v1.1., 24 months.
Efficacy endpoints: Overall response rate (ORR)., Evaluated by RECIST v1.1., 24 months|Efficacy endpoints: Duration of response (DoR)., Evaluated by RECIST v1.1., 24 months|Efficacy endpoints: Disease control rate (DCR)., Evaluated by RECIST v1.1., 24 months|Efficacy endpoints: Progression free survival (PFS)., Evaluated by RECIST v1.1., 24 months|Efficacy endpoints: overall survival (OS)., Evaluated by RECIST v1.1., 24 months
The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.